Gastrointestinal Cancers clinical trials

Explore recruiting gastrointestinal cancers clinical trials.

Recruiting gastrointestinal cancers studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrointestinal Cancers trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI)

Germany

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Spain, France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

FUDOSE: Dihydropyrimidine dehydrogenase (DPD) phenotype-guided dose individualization of fluoropyrimidinebased chemotherapy in DPD deficient patients with gastrointestinal cancers.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment comBinations with peLarEorep and aTezolizumab (GOBLET)

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Gastrointestinal Cancers trials by city

Gastrointestinal Cancers in Toronto Gastrointestinal Cancers in Vancouver Gastrointestinal Cancers in Montreal Gastrointestinal Cancers in Calgary Gastrointestinal Cancers in Edmonton Gastrointestinal Cancers in Ottawa Gastrointestinal Cancers in Winnipeg Gastrointestinal Cancers in Quebec City Gastrointestinal Cancers in Hamilton Gastrointestinal Cancers in Kitchener Gastrointestinal Cancers in London Gastrointestinal Cancers in Halifax Gastrointestinal Cancers in New York Gastrointestinal Cancers in Los Angeles Gastrointestinal Cancers in Chicago Gastrointestinal Cancers in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease